Evidence map›Paper›PMID 35216626›Full record

ArticleExperimental hematology & oncology2022

A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.

Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa, Hiroshi Nakamura, Michio Sawada, Kenji Fukuno, Yuhei Shibata, Yuto Kaneda, Takeshi Hara, Nobuhiro Kanemura and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nobuhiko NakamuraDepartment of Hematology and Infectious Disease, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan. nnaka@gifu-u.ac.jp.ORCID http://orcid.org/0000-0003-1682-7777
Senji KasaharaDepartment of Hematology, Gifu Municipal Hospital, Gifu, Japan.
Junichi KitagawaDepartment of Hematology, Gifu Municipal Hospital, Gifu, Japan.
Hiroshi NakamuraDepartment of Hematology and Infectious Disease, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan.
Michio SawadaDepartment of Hematology, Gifu Red Cross Hospital, Gifu, Japan.
Kenji FukunoDepartment of Hematology, Takayama Red Cross Hospital, Gifu, Japan.
Yuhei ShibataDepartment of Hematology, Gifu Municipal Hospital, Gifu, Japan.
Yuto KanedaDepartment of Hematology, Takayama Red Cross Hospital, Gifu, Japan.
Takeshi HaraDepartment of Hematology, Matsunami General Hospital, Gifu, Japan.
Nobuhiro KanemuraDepartment of Hematology and Infectious Disease, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan.
Hisashi TsurumiDepartment of Hematology and Infectious Disease, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan.
Masahito ShimizuDepartment of Hematology and Infectious Disease, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase II clinical trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Thirteen patients were enrolled and received a median of 4 cycles (range 2-6) of BRAC. The complete response rate was 61.5%, and the overall response rate was 84.6%; the 2-year overall survival was 76.9%, and the 2-year progression-free survival was 69.2%. Although all patients received G-CSF prophylaxis, grade 3 or higher neutropenia was observed in all cycles, and the incidence of febrile neutropenia was 20%. Grade 4 thrombocytopenia was observed in 92.5% of all cycles, and platelet transfusion was performed in 94%. Although hematological toxicity was relatively high, BRAC therapy was effective for relapsed and refractory FL or MCL. Further studies are needed to determine the optimal dose of BRAC therapy.Trial registration The UMIN Clinical Trials Registry, UMIN000009797. Registered 17 January 2013, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000011103.

Indexed as

BendamustineCytarabineFollicular lymphomaMantle cell lymphomaRituximab

Identifiers

PMID35216626
PMCPMC8876747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.